ACE and myocardial infarction: Despite the widespread use of reperfusion therapy and pharmacologic agents such as β-blockers and ACE inhibitors (Chen et al., 2025b), the long-term prognosis for patients with MI remains unsatisfactory, highlighting the need for novel therapeutic approaches targeting the underlying pathophysiology.